Olivier A.
- Country
- France
- Department
- hématologie
Research Overview
- Phase 3 Study of Isatuximab, Lenalidomide, and Dexamethasone ± Bortezomib in Non-Frail, Transplant-Ineligible Elderly Patients with Newly Diagnosed Multiple Myeloma
- Minimal Residual Disease-Adapted Strategy in Multiple Myeloma: Evaluation of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients
- Phase 3 Evaluation of Lenalidomide and Daratumumab SC Versus Lenalidomide and Dexamethasone in Frail, Newly Diagnosed Multiple Myeloma Patients Ineligible for High-Dose Therapy
Data & Insights
Has run more than one trial at 70 of 95 partner sites.
Specializations
Multiple Myeloma Treatment
The investigator specializes in advancing therapeutic strategies for multiple myeloma, with particular emphasis on minimal residual disease (MRD) assessment and treatment optimization.
- Newly Diagnosed Multiple Myeloma
- Transplant-Eligible and Ineligible Patients
- MRD-Guided Treatment Approaches
Their research encompasses both elderly and frail patient populations requiring specialized treatment protocols.
Novel Therapeutic Combinations
Focus on investigating innovative drug combinations including isatuximab, elranatamab, and daratumumab for multiple myeloma treatment.
- Immunotherapy Integration
- Targeted Therapy Approaches
- Combination Treatment Strategies
Expertise in developing personalized treatment regimens based on patient characteristics and disease response.
Stem Cell Transplantation
Investigates the role of autologous stem cell transplantation (ASCT) in multiple myeloma treatment strategies.
- Single vs Tandem Transplantation
- Consolidation Therapy
- Maintenance Treatment Approaches
Explores alternative treatment options for patients ineligible for high-dose therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.